Elizabeth Homans is a business-focused leader with an MBA from Harvard Business School. She was the CEO of Lyell Immunopharma, Inc. until December 2022. During her time at Lyell, she made significant contributions to the company's strategic goals. Notably, she...
Elizabeth Homans is a business-focused leader with an MBA from Harvard Business School. She was the CEO of Lyell Immunopharma, Inc. until December 2022. During her time at Lyell, she made significant contributions to the company's strategic goals. Notably, she experienced a considerable compensation structure during her tenure, with total earnings peaking at $18.6 million in 2021, primarily driven by stock options and bonuses. Homans also took home a severance package of $1.86 million upon her departure, which included eighteen months of salary and a full bonus for 2022. Despite a successful stint, her tenure ended with no public disputes with the company, reflecting a professional transition. Her career reflects strong leadership in the biotech sector and an inherent understanding of the business landscape, allowing her to adapt to the challenges faced by a growing company. Overall, her journey serves as a case study in navigating corporate leadership and the complexities of executive compensation in the biotechnology field.